Weekly TCF Regimen Dosing
The weekly TCF (docetaxel, cisplatin, 5-fluorouracil) regimen typically uses docetaxel 20-35 mg/m², cisplatin 20-30 mg/m², and 5-fluorouracil 350-750 mg/m² administered once weekly.
Evidence-Based Dosing Recommendations
The most robust evidence for weekly TCF dosing comes from multiple phase I/II studies in gastric and esophageal cancers, with the following validated regimens:
Standard Weekly Dosing Options
Option 1 (Most Common):
- Docetaxel: 20 mg/m² IV over 1 hour
- Cisplatin: 20 mg/m² IV over 4 hours
- 5-FU: 350 mg/m² as 24-hour continuous infusion
- Schedule: Weekly for 6 consecutive weeks, followed by 2-week break 1
Option 2 (Higher Intensity):
- Docetaxel: 25 mg/m² IV
- Cisplatin: 25 mg/m² IV
- 5-FU: 750 mg/m² as 24-hour continuous infusion
- Schedule: Weekly administration 2
Option 3 (Phase I MTD):
- Docetaxel: 40 mg/m² IV over 1 hour
- Cisplatin: 30 mg/m² IV (administered as 3-hour infusion AFTER 5-FU/leucovorin to minimize electrolyte disturbances)
- 5-FU: 2,000 mg/m² as 24-hour continuous infusion
- Leucovorin: 300 mg/m²
- Schedule: Weekly for 2 consecutive weeks every 3 weeks 3
Clinical Context and Toxicity Profile
The weekly formulation was specifically developed to reduce the severe toxicity profile of standard every-3-week DCF (docetaxel 75 mg/m², cisplatin 75-100 mg/m², 5-FU 750 mg/m² × 5 days), which causes grade 3-4 neutropenia in 82% and febrile neutropenia in 29% of patients 4.
Weekly regimen toxicity is substantially lower:
- Grade 3-4 neutropenia: 4-28% (versus 82% with standard DCF)
- Febrile neutropenia: 0-13% (versus 29% with standard DCF)
- Grade 3-4 anemia: 9-10%
- Grade 3-4 thrombocytopenia: 8%
- Non-hematologic grade 3-4 toxicity: <10% 2, 1
Efficacy Data
Weekly TCF demonstrates reasonable efficacy despite dose reduction:
- Overall response rate: 26-48% in advanced gastric cancer
- Median time to progression: 4-6 months
- Median overall survival: 8.9-12 months
- Disease control rate: 58% 2, 1, 5
Important Administration Details
Critical modification to prevent electrolyte disturbances: Administer cisplatin as a 3-hour infusion AFTER the 5-FU/leucovorin infusion, not concurrently. Early studies using 24-hour cisplatin infusion concurrent with 5-FU caused grade 2-3 hypomagnesemia and hypokalemia in 41% and 18% of patients respectively. This complication was eliminated by changing the cisplatin schedule 3.
Patient Selection
Weekly TCF is specifically indicated for patients who are:
- Not candidates for standard every-3-week DCF due to:
- ECOG performance status 1-2
- Age ≥65 years
- Borderline organ function
- Concern for tolerability of intensive regimen
Pediatric Dosing
In pediatric patients (ages 9-21 years), the FDA-approved dosing for TCF is:
- Docetaxel: 75 mg/m² IV day 1
- Cisplatin: 75 mg/m² IV day 1
- 5-FU: 750 mg/m² continuous infusion days 1-5
- Cycle: Every 3 weeks 6
Note: This is NOT a weekly regimen but the standard 3-weekly schedule used in pediatric nasopharyngeal carcinoma.
Common Pitfalls
- Do not use weekly dosing for curative-intent treatment where standard DCF is indicated (e.g., perioperative gastric cancer in fit patients)
- Monitor electrolytes closely if using concurrent cisplatin/5-FU infusion
- Adjust for renal function - cisplatin requires adequate creatinine clearance
- Growth factor support is generally not required with weekly dosing (unlike standard DCF which requires routine G-CSF)
The weekly TCF regimen represents a reasonable palliative treatment option with substantially improved tolerability compared to standard DCF, making it appropriate for patients with advanced disease and compromised performance status.